Clariant is set to unveil its new anti-counterfeiting solution, Plastiward, at the ongoing Pharmapack Europe 2017 event.

Developed in collaboration with Sicpa, Plastiward is a plastic-based brand-protection system that can be used in packaging for pharmaceutical products, including medical devices.

Plastiward features a proprietary covert taggant, which is produced by Sicpa and delivered to a Clariant plant.

The taggant is then incorporated into various polymers used in medical devices and pharmaceutical packaging, either in a concentrated masterbatch form, or as a finished polymer compound.

"The mission of safe access to treatments remains a challenge to medical devices and pharmaceutical companies despite investments in fighting fakes."

Clariant global segment healthcare polymer solutions head Steve Duckworth said: “Counterfeit medical devices pose a significant liability to their manufacturers and healthcare providers, and a risk of injury, permanent disability or even death to patients.

“The mission of safe access to treatments remains a challenge to medical devices and pharmaceutical companies despite investments in fighting fakes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“As it is well accepted that layers of security features are necessary, the unique features of PLASTIWARD can help reinforce this approach.”

Duckworth also noted that a World Health Organisation report shows that up to 8% of the medical devices in circulation are counterfeit.

Interpol has also estimated that $75bn worth of counterfeit pharmaceuticals enter the market every year.